
Immunome, Inc.
IMNM
IMNM: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.
moreShow IMNM Financials
Recent trades of IMNM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMNM's directors and management
Government lobbying spending instances
-
$10,000 Jul 16, 2022 Issue: Health Issues
-
$10,000 Oct 18, 2021 Issue: Health Issues
-
$20,000 Jul 20, 2020 Issue: Health Issues
New patents grants
Federal grants, loans, and purchases
Followers on IMNM's company Twitter account
Number of mentions of IMNM in WallStreetBets Daily Discussion
Recent insights relating to IMNM
Recent picks made for IMNM stock on CNBC
ETFs with the largest estimated holdings in IMNM
Flights by private jets registered to IMNM